Following its recent $11.1 billion Salix buy and a boosted revenue forcast, Valeant has announced two key executive staff changes.
First, Valeant chief financial officer Howard Schiller, touted as "a key player in the serial acquisition strategy" by Montreal media sources, plans to resign once a successor is named.
Additionally, Valeant has appointed the former president and CEO of biotech company Synta Pharmaceuticals, Anne Whitaker, as Valeant executive vice president and group chairman. Prior to joining Synta, Whitaker was president of North American Pharmaceuticals for Sanofi.